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Amplification of chromosomal region 8p11-12 is a frequent genetic alteration implicated in the 
etiology of lung squamous cell carcinoma (LUSC)1-3. FGFR1 (fibroblast growth factor receptor 1) 
is the main candidate driver within this region4. However, clinical trials evaluating FGFR1 
inhibition as a targeted therapy have been unsuccessful5. Here we identify the H3K36 
methyltransferase NSD3 (nuclear receptor binding SET domain protein 3), an 8p11-12-localized 
gene, as a key regulator of LUSC tumorigenesis. In contrast to other 8p11-12 candidate LUSC 
drivers, increased NSD3 expression strongly correlates with its gene amplification. Ablation of 
NSD3, but not FGFR1, attenuates tumor growth and extends survival in a potent LUSC mouse 
model. We identify NSD3T1232A as an LUSC-associated variant that increases H3K36 
dimethylation (H3K36me2) catalytic activity in vitro and in vivo. Structural dynamic analyses 
reveal that the T1232A substitution elicits localized mobility changes throughout NSD3’s catalytic 
domain to relieve auto-inhibition and increase H3 substrate accessibility. NSD3T1232A expression 
in vivo accelerates tumorigenesis and decreases overall survival in LUSC mouse models. 
Pathologic H3K36me2 generation by NSD3T1232A rewires the chromatin landscape to promote 
oncogenic gene expression programming. Further, NSD3’s catalytic activity promotes human 
tracheobronchial cell transformation and xenograft growth of human 8p11-12-amplified LUSC 
cell lines. NSD3 depletion in patient-derived xenografts (PDXs) from primary LUSC harboring 
NSD3 amplification or the NSD3T1232A variant attenuates neoplastic growth. Finally, NSD3-
regulated LUSC PDXs are markedly sensitive to bromodomain inhibition (BETi). Together, our 
work identifies NSD3 as a principal 8p11-12 amplicon-associated oncogenic driver in LUSC and 
suggests that NSD3-dependency renders LUSC therapeutically vulnerable to BETi.
NSD3, not FGFR1, promotes LUSC in vivo
Many genes present within the 8p11-12 amplicon could potentially contribute to 
oncogenesis (Extended Data Fig. 1a). However, the minimal region of amplification across 
many 8p11-12-signature neoplasms centers around FGFR1 and the neighboring gene and 
candidate oncogene NSD33,4,6,7. Indeed, analysis of LUSC datasets from The Cancer 
Genome Atlas (TCGA) shows that NSD3 and the immediate neighboring genes (e.g. 
FGFR1) are the most commonly amplified 8p11-12 genes (Extended Data Fig. 1a). Overall, 
amplification of the genomic area spanning the NSD3 and FGFR1 genes is one of the more 
common molecular alterations in LUSC (Extended Data Fig. 1b). Notably, for NSD3, gene 
amplification strongly correlates with increased mRNA expression; in contrast, there is little 
correlation between FGFR1 gene copy number and mRNA expression (Fig. 1a; Extended 
Data Figs. 1a-b)2,3. Accordingly, sgRNA-mediated depletion of NSD3, but not depletion of 
FGFR1 or the gene immediately adjacent to NSD3 (PLPP5), in the 8p11-12 amplified 
(8p11AMP) H520 LUSC cell line inhibited xenograft tumor growth (Fig. 1b; Extended Data 
Figs. 2a-e). These data point to NSD3, rather than FGFR1, as the mutational driver within 
the 8p11-12 amplicon in LUSC.
We next established a robust LUSC mouse model consisting of canonical LUSC alterations 
co-occurring with 8p11-12 amplification (constitutively active PI3K, SOX2 overexpression, 
and CDKN2A/B deletion, hereto named PSC mice; (see Extended Data Fig. 1b and 
Methods). PSC mice develop with high penetrance lung tumors characterized by LUSC-
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defining molecular hallmarks (Extended Data Fig. 2f)8. In this model, increased NSD3 
expression tracks with tumor progression, consistent with NSD3 overexpression observed in 
~60% of LUSC samples (beyond the 20% harboring 8p11AMP) and frequently co-occurring 
with PSC molecular alterations (Extended Data Figs. 2g-i).
Conditional FGFR1loxP/loxP and NSD3loxP/loxP mutant mice were generated and are viable, 
fertile and develop normally (see Methods). In the PSC background, targeted deletion in the 
lung of NSD3 (PSCNSD3-KO) (Fig. 1c), but not FGFR1 (PSCFGFR1-KO) (Fig. 1d), 
significantly attenuated tumor growth and cancer cell proliferation, while increasing 
apoptosis (Fig. 1e; Extended Data Figs. 2j-l). In survival studies, deletion of NSD3 extended 
lifespan of PSC mice by ~30%, whereas FGFR1 knockout had no impact (Fig. 1f). Together, 
these data support a key in vivo role for NSD3 in LUSC tumorigenesis.
NSD3T1232A is a hyperactive variant
NSD3, along with NSD1, NSD2, and ASH1L, comprise the four enzymes in mammals that 
specifically synthesize the euchromatin-associated H3K36me2 modification (reviewed in 9). 
Depending on cell type, NSD1 and NSD2 are the major H3K36me2-generating enzymes, 
whereas the physiologic context in which NSD3 regulates H3K36me2 is less clear9. We 
observed lower global H3K36me2 levels in NSD3-deleted lung tumor tissue compared to 
control tumors (Fig. 1c), suggesting an etiological role for NSD3-catalyzed H3K36me2 
synthesis in NSD3 amplified-LUSC. We reasoned this idea could be tested in mice by 
transgenic expression of an NSD3 hyperactive variant, which would model the consequence 
of increased NSD3 catalysis due to elevated NSD3 dosage on tumorigenesis. A recurrent 
hyperactivating NSD2 mutation is present in different cancers9, suggesting that a 
functionally analogous cancer-associated mutation may be present in NSD3. To this end, we 
tested in vitro histone methylation activity for 35 different TCGA-documented mutations 
within the NSD3 catalytic domain (Extended Data Figs. 3a-c). The variant showing the 
highest activity was the T1232A substitution (NSD3T1232A), a recurrent cancer-associated 
mutation10.
The in vitro methylation activity on nucleosomes of recombinant NSD3 catalytic domain 
harboring the T1232A substitution (NSD3SET-T1232A), which is stronger than wild-type 
(NSD3SET) enzyme, is abrogated when paired with a catalytic mutant 
(NSD3SET-T1232A/Y1174A) (Figs. 2a-b; Extended Data Fig. 3d). Further, NSD3SET-T1232A 
was more efficient in selectively generating H3K36me2 relative to wild-type enzyme (Fig. 
2b). Despite the higher activity, NSD3SET-T1232A behaved similar to NSD3SET with respect 
to (i) nucleosomal versus free H3 substrate preference (Fig. 2a), (ii) methylation state 
specificity, generating H3K36me1/2 but not H3K36me3 (Fig. 2b), and (iii) site-specific 
selectivity, methylating K36, but not several other histone lysine residues (Fig. 2b). 
Recombinant full-length NSD3T1232A behaves like the isolated catalytic domain in being 
hyperactive while retaining the same catalytic selectivity profile (Fig. 2c). Finally, 
overexpression of NSD3T1232A, but not NSD3WT or NSD3T1232A/Y1174A, increases 
H3K36me2 levels in NSD2-depleted HT1080 fibrosarcoma cells (Extended Data Fig. 3e). 
These findings identify NSD3T1232A as a hyperactive cancer-associated mutant.
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The enhanced activity of NSD3SET-T1232A versus NSD3SET is more evident when using 
nucleosomes with longer linker DNA (187 versus 147 base-pairs) (Extended Data Fig. 3f). 
The mechanism behind the increased catalysis, irrespective of linker DNA, is not mediated 
by the T1232A substitution significantly altering NSD3’s binding affinity for nucleosomes 
or the cofactor methyl donor S-adenosyl-L-methionine (SAM) (Extended Data Fig. 4a; 
Supplementary Table 1). High-resolution nuclear magnetic resonance (NMR) comparison of 
the protein backbone of NSD3SET-T1232A and NSD3SET in solution shows that the static 
structure is largely unaffected by the T1232A substitution (Extended Data Figs. 4b-c; 
Supplementary Table 1). In contrast, chemical shift perturbations (CSPs) of the backbone 
amide 1H/15N resonances, which serve as sensitive probes for local structural and allosteric 
effects, were observed throughout the SET domain (Fig. 2d; Extended Data Figs. 4c-d). The 
highest CSPs are centered around T1232A, with effects extending throughout the substrate-
binding cleft and include the conserved NSD3 auto-regulatory loop (Fig. 2d; Extended Data 
Figs. 4d-e)11,12. Consistent with these findings, backbone 15N spin relaxation studies 
revealed multiple differences in local dynamics between NSD3SET-T1232A and NSD3SET 
concentrated at the substrate-binding cleft and auto-regulatory loop regions (Fig. 2e; 
Extended Data Figs. 4g-h; Supplementary Table 1). These data suggest that T1232A 
increases activity by (1) enhancing the mobility of the auto-regulatory loop, which 
destabilizes the inhibitory state, acting in concert with (2) the active site being rendered 
more accessible to the H3 substrate and (3) direct, localized modification of the H3 binding 
surface. Indeed, the polar hydroxyl group loss with T1232A increases local hydrophobicity, 
which can alter H3 anchoring dynamics (Figs. 2d-e)13. Introduction of a second alanine 
substitution at V1243, a residue adjacent to A1232 in the structure (T1232A/V1243A), is 
predicted to restore local surface hydrophobicity13. Accordingly, methylation activity of a 
double alanine mutant (NSD3SET-T1232A/V1243A) is similar to wild-type enzyme and lower 
than activity of the single mutant (NSD3SET-T1232A), while the NSD3SET-V1243A shows no 
activity and decreased thermal stability (Extended Data Fig. 4i; Supplementary Table 1). 
Thus, T1232A substitution induces local dynamics changes at many residues within three 
key functional regions of the NSD3 catalytic domain that likely work in concert to increase 
H3K36 methylation catalysis.
H3K36me2 deregulation accelerates LUSC
NSD3T1232A was next used to model consequences of elevated catalytic activity due to 
NSD3 amplification on LUSC tumorigenesis in vivo. Murine and human NSD3 are highly 
similar (94% overall; 98% in the catalytic domain) with murine NSD3 (mNSD3) T1242 
corresponding to human T1232 (Extended Data Fig. 5a). We generated Cre-inducible V5-
tagged mNSD3T1242A mice and transgene expression was verified in lung fibroblast cells 
transduced with Ad-Cre ex vivo (Extended Data Figs. 5b-e). In the PSC background, 
expression of mNSD3T1242A (hereto named PSCN) accelerated tumor growth (Figs. 3a-b) 
and proliferation (Figs. 3c-d) while decreasing apoptosis (Extended Data Figs. 5f-g) relative 
to the control PSC group. For example, at 90 days after Cre-induction, when PSC mice have 
no detectable tumors, multiple growths are observed in the PSCN cohort (Fig. 3a). At 120 
days, tumor burden in PSCN mice is over an order of magnitude greater than in control PSC 
mice (Figs. 3a-b). Consistent with these data, expression of mNSD3T1242A reduced PSC 
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mice lifespan by ~30% (Fig. 3e). In independent LUSC tumor biopsies, high NSD3 levels 
(due to mNSD3T1242A expression) result in markedly elevated H3K36me2 (Fig. 3f; 
Extended Data Fig. 5f). Moreover, mNSD3T1242A-driven tumors have higher levels of 
oncoproteins MYC and BRD4 and phosphorylated 4EBP1 (a proxy for mTOR pathway 
activation) (Fig. 3f). Together, these data indicate that NSD3’s activity significantly impacts 
the clinical course and outcome of LUSC in vivo.
Comparison of cell lines derived from mNSD3T1242A and control PSC matched tumors 
(hereto named PSCN and PSCC, respectively) show that H3K36me2 levels in cells, like in 
tumors, are higher if expressing the mNSD3T1242A transgene (Extended Data Fig. 5h). 
Further, NSD3 depletion in PSCN cells results in depletion of H3K36me2 (Fig. 3g). Based 
on transcriptomic experiments, the impact of mNSD3T1242A expression status on the total 
number of differentially expressed genes (DEGs) is, as expected, far greater when 
comparing PSCN to PSC tumor biopsies than for PSCN cells ±NSD3 depletion, in which 
NSD3 was depleted for a relatively short time prior to the analysis (Extended Data Figs. 5i-j; 
Supplementary Tables 2-3). Nonetheless, the gene set enrichment analysis (GSEA) profiles 
of the tumor and cellular datasets show highly significant overlap with the same pathways, 
including strong correlations with MYC targets and mTOR signaling signatures (Fig. 3h; 
Extended Data Fig. 5k). We note that regulation of these genes (e.g. Prkaa2, Myc and Irgm1) 
was observed in independent NSD3 depleted cell lines and dependent on NSD3’s catalytic 
activity (Extended Data Figs. 5l-m).
Next, Cleavage Under Targets and Release Using Nuclease (CUT&RUN)14 was used to 
profile the genomic distribution of H3K36me2 in PSCN cells ±NSD3 depletion. We also 
mapped H3K27me3 as the deposition of this important chromatin modification is directly 
antagonized by H3K36 methylation (reviewed in 9). An averaged genome-wide distribution 
of H3K36me2 in PSCN cells across all gene bodies shows that the signal peaks 5’ of the 
transcription start site (TSS), with a second smaller peak 3’ of the TSS, followed by a slow 
decay towards the 3’ end of genes (Fig. 3i; Extended Data Fig. 6a). Upon NSD3 depletion, 
the intensity of the H3K36me2 signal is proportionally lower across the averaged gene unit 
with little change in the overall pattern (Fig. 3i; Extended Data Fig. 6a). In contrast, the 
NSD3-dependent distribution of H3K36me2 specifically at the gene bodies of 
downregulated DEGs (dDEGs), the most likely direct targets of NSD3, diverges from the 
overall genome-wide pattern in two ways: (i) the baseline signal is 2-3 fold higher and (ii) 
the signal distribution across the gene is distinct, with the most intense peak being 3’ – 
rather than 5’ – proximal to the TSS (Fig. 3i; Extended Data Fig. 6a). Furthermore, 
quantitation of the difference between H3K36me2 peak signal intensities ±NSD3 depletion 
reveals that the magnitude of peak change at dDEGs gene bodies is significantly greater than 
the change observed genome-wide (Fig. 3j). Notably, relative to other genes, dDEGs show 
both high H3K36me2 chromatin signal and high mRNA transcript levels (Extended Data 
Fig. 6b). These data suggest that robust transcription may predispose genes to NSD3 
deregulation.
For H3K27me3, there is an overall increase in signal intensity upon NSD3 depletion 
genome-wide and at dDEGs, with no quantitative difference in the magnitude of change 
between the two gene groups (Figs. 3i-j). The inverse relationship between H3K36me2 and 
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H3K27me3 in relation to NSD3 status extends to intergenic regions (Extended Data Fig. 6c-
d). The pattern of diminished H3K36me2 and increased H3K27me3 upon NSD3 depletion is 
also observed at the level of individual dDEG tracks (Extended Data Fig. 6e). Finally, using 
chromatin immunoprecipitation (ChIP) assays, we observe a reduction in occupancy of 
mNSD3T1242A and H3K36me2 at target genes (Prkaa2 and Irgm1) upon NSD3 depletion, 
which was reconstituted to control levels by complementation with catalytically active, but 
not catalytically-dead, NSD3 (Extended Data Figs. 6f-h). Together, these data suggest that 
aberrant H3K36me2 synthesis by NSD3 directly regulates an LUSC-advancing gene 
expression program.
NSD3 promotes human LUSC tumorigenesis
To explore the role of NSD3 in human LUSC, we assembled the majority of publicly 
available human LUSC cell lines, including all five available 8p11AMP cell lines, an 
8p11AMP-negative NSD3-overexpressing cell line with a PSC-like genetic background, and 
six 8p11AMP-negative control cell lines lacking NSD3 overexpression (Fig. 4a; Extended 
Data Fig. 7a). NSD3 depletion impaired xenograft tumor formation in the 8p11AMP/NSD3-
overexpressing human LUSC cell lines but did not affect tumor growth in the six control cell 
lines (summarized in Fig. 4a; see Extended Data Fig. 4b). The phenotype in the five 
8p11AMP LUSC lines is unlikely resulting from non-specific DNA damage due to sgNSD3-
targeted cutting within amplified regions15 as: (i) sgFGFR1 and sgPLPP5 had no effect on 
xenograft growth in 8p11AMP-positive H520 cells (Extended Data Fig. 2e), (ii) γH2AX 
levels were not altered by sgNSD3 treatment in 8p11AMP cell lines (Extended Data Figs. 2d 
and 7b), and (iii) depletion of NSD3 in the 8p11AMP LUSC cell lines by RNAi also 
attenuated xenograft growth (Fig. 4a; Extended Data Fig. 7c). Finally, complementing 
NSD3-depleted H520 cells with NSD3WT and NSD3T1232A reconstituted xenograft tumor 
growth, whereas catalytically-dead NSD3 and a short NSD3 isoform lacking the catalytic 
domain (NSD3short) previously implicated in breast cancer pathogenesis6 both failed to 
reconstitute full xenograft growth (Fig. 4b; Extended Data Fig. 7d).
We next investigated the ability of NSD3 to cooperate with SOX2 to transform human 
tracheobronchial epithelial (AALE) cells16. As previously reported, ectopic expression of 
SOX2 with a second transcription factor (FOXE1) promotes anchorage-independent growth 
of AALE cells16. We found that ectopic expression of SOX2 with either NSD3WT or 
NSD3T1232A was more efficient in transforming AALE cells than SOX2/FOXE1, with 
SOX2/NSD3T1232A showing the greatest promotion of anchorage-independent growth in 
vitro (Extended Data Figs. 7e-g) and tumor growth in vivo (Fig. 4c; Extended Data Figs. 
7e,h). In contrast, catalytically-dead NSD3 and NSD3short failed to promote AALE 
transformation (Fig. 4c; Extended Data Figs. 7e-h). Together, these data argue that NSD3, 
via its catalytic activity, promotes tumor growth of human LUSC cells and oncogenic 
transformation of human AALE cells.
To further investigate roles of the NSD3-H3K36me2 axis in human cancer a collection of 37 
LUSC PDX samples was screened for NSD3 alterations. Of these, one was NSD3T1232A 
positive (PDXT1232A), twelve were NSD3 amplification positive (PDXAMP), and the others 
had no NSD3 alteration (PDXCTR) (Extended Data Fig. 8; data not shown). Four PDXs 
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(PDXT1232A, PDXAMP-1, and two controls (PDXCTR)), which apart from the NSD3 
alterations have similar mutational profiles (e.g. PSC-signature), were selected for further 
analysis. In comparison to PDXCTR samples, NSD3 levels are higher in PDXT1232A cells 
and highest in PDXAMP-1 cells (Fig. 4d). H3K36me2 levels in the PDXT1232A and 
PDXAMP-1 cells are comparable to one another and elevated relative to controls (Fig 4d); 
similar H3K36me2 abundance in PDXT1232A and PDXAMP-1 cells, while the former has 
lower NSD3 levels, is consistent with NSD3T1232A hyperactive. NSD3 depletion, which 
resulted in H3K36me2 loss, attenuated growth of PDXT1232A and PDXAMP-1 xenograft 
tumors (Figs. 4e-g) but did not impact growth of PDXCTR samples (Extended Data Figs. 9a-
b). PDX growth inhibition upon NSD3 depletion was also seen with an independent 
8p11AMP PDX sample (Extended Data Fig. 9c). Thus, a subset of PDXs from primary 
LUSC human tumors are NSD3-regulated and selectively sensitive to NSD3 depletion.
NSD3 sensitizes LUSC to BETi therapy
While at present there is no NSD3 catalytic inhibitor that can be used in a physiologic 
setting, we speculated that selection for NSD3-dependency may confer adaptive 
vulnerability of LUSC to drugs targeting known cancer pathways. To test this idea, we 
screened a library comprising 285 characterized inhibitors covering ~170 cancer targets to 
identify drugs that have increased efficacy in PSCN versus PSCC cells. The four BETi drugs 
present in the library exhibited the highest differential lethality, consistent with BRD4 
interacting directly with NSD3 in LUSC cells (Supplementary Table 4; Extended Data Fig. 
9d)17,18. Under normal conditions, PSCN cells proliferate more rapidly than PSCC cells 
(Extended Data Fig. 9e). However, treatment with the BETi AZD515319, which has a 
modest effect on PSCC cell proliferation, inhibits NSD3-target gene expression and 
proliferation of PSCN cells (Extended Data Fig. 9e-f). NSD3-dependent BETi sensitivity 
was also observed in PDXs; actively growing PDXT1232A and PDXAMP tumors stall in 
response to BETi treatment, a phenotype that is weakened by NSD3 depletion (Figs. 4h-i). 
In contrast, PDXCTR samples are moderately responsive to BETi therapy independent of 
NSD3 (Extended Data Figs. 9g-h). Thus, the oncogenic advantage provided by NSD3 to 
LUSC potentially comes with a cost – BETi-hypersensitivity – a clinically actionable 
vulnerability.
Summary
LUSC, one of the leading causes of cancer-related mortality worldwide, is characterized by 
several well-defined driver mutations. However, in contrast to malignancies like lung 
adenocarcinoma in which targeted therapy approaches have been encouraging, translating 
similar strategies for LUSC has been challenging. Our study has uncovered a pivotal role for 
NSD3 in LUSC, a finding with potential prognostic and therapeutic relevance for the 
estimated 100,000 patients diagnosed worldwide each year with 8p11AMP-LUSC20. We 
propose a model in which NSD3, via H3K36me2, acts as an epigenetic deregulator to 
facilitate expression of oncogenesis-promoting genes (Extended Data Fig. 10). The genes 
most acutely impacted by NSD3 are marked by high basal H3K36me2 and are robustly 
transcribed. These features are consistent with the vulnerability of NSD3-regulated LUSC to 
BETi, as this drug class targets active transcription21. Indeed, NSD3 depletion was recently 
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identified as a strong sensitizer of acute myeloid leukemia cells to BETi22. Thus, while 
clinical NSD3 inhibitors are presently unavailable, the increased sensitivity of NSD3-
regulated LUSC to BETi may expand the narrow therapeutic window for these medicines21. 
Finally, NSD3’s oncogenic activity likely extends beyond LUSC, as the 8p11-12 amplicon is 
a common molecular signature of breast cancer and other malignancies7.
METHODS
Plasmids.
The cloning of full-length NSD3 and NSD3SET (aa1021-1320) was based on NCBI 
sequence NM_023034.2. Full length NSD3 was cloned into pCAG vector for transient 
transfection or into pENTR3C entry vector for subsequent cloning into pLenti-CMV-hygro 
(w117-1) destination vector for expression in HT1080 cells. Different versions of V5-NSD3 
(WT, T1232A, Y1174A, T1232A/Y1174A or Short), SOX2 and V5-FOXE123 and AkaLuc 
(gift from Dr. Michael Z. Lin)24 were cloned into pENTR3C entry vector for subsequent 
cloning into pPB-CAG-Dest-pA-pgk-bsd (Addgene) destination vector for reconstitution in 
H520 cells or into pPB-CAG-Dest-IRES-puro destination vector for transformation in 
AALE cells 23. NSD3SET was cloned into pGEX-6P-1 vector and all the different mutant 
versions of NSD3SET were generated by site-directed mutagenesis. The choice of residue 
Y1174A as a catalytic mutant of NSD3 was based on its homology to a validated NSD2 
catalytic mutant (Y1092A)25 and independently shown to abrogate NSD3 catalytic activity 
(data not shown). Wildtype and T1232A mutant versions of NSD3SET (aa1055-1285) were 
cloned into pQE30 vector for NMR analysis.
Immunoblot analysis and co-immunoprecipitation.
For western blot analysis, cells were lysed in RIPA buffer with 1 mM PMSF and protease 
inhibitor cocktail. Protein concentration was determined using the Pierce Coomassie Plus 
Assay. Protein samples were resolved by SDS-PAGE and transferred to a PVDF membrane. 
The following antibodies were used (at the indicated dilutions): H3K36me2 (Thermo Fisher 
Scientific #701767, 1:1000), H3K36me3 (Thermo Fisher Scientific #MA5-24687, 1:1000), 
H3K27me3 (Thermo Fisher Scientific #MA5-33081, 1:1000), V5 (Thermo Fisher Scientific 
#R960-25, 1:1000), H3K36me1 (Abclonal #A2364, 1:5000); H3K4me2 (CST #9725S, 
1:1000), H3K9me2 (CST #4658S, 1:1000), H3K27me2 (CST #9728S, 1:1000), γH2AX 
(CST ##9718, 1:1000), SOX2 (CST #3579, 1:1000), c-Myc (CST #5605S, 1:1000), 
Phospho-4E-BP1 (CST #2855S, 1:1000), 4E-BP1 (CST #9644S, 1:1000), FGFR1 (CST 
#9740S, 1:1000), H4K20me2 (Abcam #ab9052, 1:1000), H3 (Abcam #ab1791, 1:5000), 
BRD4 (Abcam #ab128874, 1:1000), β-Actin (CST #4970, 1:5000), β-Tubulin (Millipore 
#05-661, 1:5000), NSD225 (1:500), NSD3 antibody (1:1000) was generated using protein 
fragment corresponding to amino acid residues 1021-1320 of NSD3 (to detect full-length 
NSD3 but not NSD3short) as the epitope to generate antiserum (Genemed Synthesis Inc.) 
followed by purification with immobilized epitope, NSD3 (CST #92056S, 1:1000) was used 
for detecting both NSD3 and NSD3Short.
For co-immunoprecipitation, nuclear extracts were incubated with 4 μg BRD4 antibody or 
IgG control overnight at 4°C. Extracts were then incubated with protein A Sepharose beads 
Yuan et al. Page 8













for 2 hours at 4°C then washed and eluted in 2× sample buffer at 98 °C. Eluates and nuclear 
extract (input sample) were resolved by SDS-PAGE, transferred to a PVDF membrane and 
immunoblotted
Preparation of recombinant proteins, nucleosomes, and DNA.
E.coli BL21-RIL cells transformed with respective expression vectors were cultivated in 
2xYT or M9 media at 20°C for 16-20 hours. Cells were lysed using a French press 
(Constant Systems TS-Series) and lysates were cleared by centrifugation at 14000 rpm for 1 
hour and subsequently injected into a HiTrap SP FF 5 ml column followed by elution with a 
salt gradient. Fractions containing NSD3SET/NSD3SET-T1232A expressed from pGEX-6P-1 
were collected and injected into a GSTrap HP 5 ml column followed by elution with a 
gluthatione gradient. Eluate was mixed with GST-PreScission protease in a 100:1 ratio and 
dialyzed overnight at 4°C against storage buffer (50 mM TRIS/TRIS-HCl, pH = 7.5, 150 
mM NaCl, 1 mM TCEP). Final purification was achieved by passing through a GSTrap HP 5 
ml column, the flow through was collected and contained proteins were concentrated with an 
Amicon 3000 MWCO. Proteins expressed from pQE30 were purified with the help of a 
nickel affinity column HisTrap FF 5 ml, and then dialyzed overnight at 4°C against final 
NMR buffer. For the high-resolution NMR structural and dynamics studies, U-[15N], 
U-[13C,15N] NSD3SET and NSD3SET-T1232A versions were prepared from pQE30 vector by 
expression in M9 media. 15NH4Cl at a concentration of 1 g/L served as sole source of 
nitrogen, for U-[13C,15N] labeling a 13C-glucose (CIL) at 3 g/L was added. Recombinant 
nucleosomes were assembled using 601 Widom DNA26. The 601 Widom DNA with 20bp 
overhang (187bp) and without overhang (147bp) were prepared by PCR and purified by 
phenol/chloroform extraction and isopropanol precipitation. The Cy5-labeled dsDNA 
(147bp or 187bp) was prepared by annealing oligonucleotides 187-F Cy5-
CGAGGCTGTTCAATACATGC, 187-R GGACCCTATACGCGGCC, 147-F Cy5-
CTGGAGAATCCCGGTGCCGAGGC, 147-R 
ACAGGATGTATATATCTGACACGTGCCTG in equimolar ratio at 10 M concentration via 
heating to 95°C and slow cooling at 0.1°C/5 s in a PCR thermocycler. Human H2A and H2B 
histones were prepared according to previously described protocol27. Histone octamers and 
nucleosomes were assembled according to methods described previously28.
Purification of Recombinant Full-Length NSD3.
HEK 293T cells were transfected with pCAG-FLAG-NSD3 (WT or NSD3 mutants) or 
empty vector. Cells were lysed with buffer containing 10 mM HEPES (pH = 7.9), 1.5 mM 
MgCl2, 10 mM KCl to deplete cytoplasmic fractions, the pellet was treated with buffer 
containing 20 mM HEPES (pH = 7.9), 1.5mM MgCl2, 420 mM KCl, 0.2 mM EDTA, 10% 
glycerol, 0.2 mM PMSF and proteinase inhibitor cocktail (Roche) to get nuclear extract. The 
nuclear extract was diluted to contain 300 mM KCl, full-length NSD3 was affinity-purified 
with anti-FLAG(M2)-conjugated agarose (Sigma) from the diluted nuclear extract and 
eluted with 0.5 mg/ml FLAG peptides for in vitro methylation assays.
In vitro methylation assay.
In vitro methylation assays were performed as previously described29 using 2 μg of enzyme 
(unless otherwise noted) and 2 μg of recombinant nucleosomes (EpiCypher, catalog#s: 
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16-0009 and 16-2004) or recombinant histone H3 (generated as describe in 30) in the 
presence of 3H-SAM(S-adenosyl-L-methionine) or non-radiolabeled SAM.
Cell lines, primary cell cultures and cell assays.
HEK-293T (ATCC #CRL-1573), KNS-62 (JCRB #IFO50358), SK-MES-1 (ATCC 
#HTB-58), HT1080 (ATCC #CCL-121) cells were grown in DMEM medium supplemented 
with 10% fetal calf serum, 2 mM L-glutamine and penicillin–streptomycin (Life 
Technologies). H520 (ATCC #HTB-182), H1703 (ATCC #CRL-5889), HCC15 (DSMZ 
#ACC496), HCC95 (KCLB #70095), VMRC-LCP (JCRB #0103), EBC-1 (RIKEN 
#RCB1965), LK-2 (RIKEN # RCB1970), RERF-LC-Sq1 (JCRB #1019), LUDLU-1 
(ECACC # 92012463) cells were grown in RPMI 1640 medium supplemented with 10% 
fetal calf serum, 2 mM L-glutamine and penicillin–streptomycin (Life Technologies). H1869 
(ATCC #CRL-5900) cells were grown in DMEM/F12 medium supplemented with 10% fetal 
calf serum, 2 mM L-glutamine and penicillin–streptomycin (Life Technologies). Primary 
mouse cancer cell lines were prepared from tumor biopsies isolated from indicated mouse 
models according to the methods previously described 31. Primary mouse cancer cell lines 
were cultured in DMEM medium supplemented with 10% fetal calf serum, 2 mM L-
glutamine and penicillin–streptomycin (Life Technologies). Primary cultures of mouse lung 
fibroblast were prepared from indicated mice using standard methods32. Briefly, mice were 
euthanized by CO2 asphyxiation and perfused with 5 ml of normal saline. Lungs were 
sterilely removed and cut into small 2-mm slices and allowed to adhere on tissue culture 
plate. Lung tissue explants were cultured in DMEM medium supplemented with 10% fetal 
calf serum, 2 mM L-glutamine and penicillin–streptomycin (Life Technologies). Lung 
fibroblasts were purified by repeat trypsinization and passaging to achieve a homogenous 
population. Lung fibroblasts were treated with Adenovirus-Cre or vehicle (PBS). Lysates 
were obtained for Western blot analyses 72 hours post transduction. All cells were cultured 
at 37°C in a humidified incubator with 5% CO2. Cell lines were authenticated by short 
tandem repeat profiling and tested negative for mycoplasma (PromoKine). Cell proliferation 
assays and drug screen was performed as previously described33. Briefly, cells were seeded 
at 5 × 103 cells/mL in triplicate in 96-well plates. Confluency of cells treated was measured 
using live cell kinetic imaging system (IncuCyte Zoom) for 120 h with data collection every 
4h. Data are represented as mean ± SEM (three independent experiments).
Transfection and Viral Transduction.
Transient expression was performed using TransIT-293 (Mirus Bio) following the 
manufacturer’s protocol. For NSD3 reconstitution, different versions of NSD3 gene were 
constructed into pPB-CAG-Dest-pA-pgk-bsd (Addgene) and transiently co-transfected with 
transposase into recipient cells with Lipofectamine 3000 (Invitrogen) following the 
manufacturer’s protocol. After 48 hours of transfection, cells were selected with 5 μg /mL 
blasticidin for 6 days, then CRISPR mediated knockdown of endogenous NSD3 was 
performed in the selected cells. For CRISPR-Cas9 or shRNA knockdowns, virus particles 
were produced by co-transfection of 293T cells with the lentiCRISPRv2/puro (Addgene) 
construct expressing indicated guide RNAs or pLKO.1/puro (Addgene) construct expressing 
indicated shRNAs, psPAX2 and pCMV-VSVg in a ratio of 5:3:2 by mass. The following 
guide RNA or shNRA oligo sequences were utilized: sgControl 
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CTTCGAAATGTCCGTTCGGT, sgNSD2 ACTCGTTAACAAATTCTCCC (made by 
Saumya Sankaran), sgNSD3 GGATACTGATTATATGAC, sgFGFR1 
TCCCCGACCTTGCCTGAACA, sgPLPP5 CAATAAAACTGATCGTAGGG, shControl 
CCTAAGGTTAAGTCGCCCTCG, shNSD3 GCAGATTGTTTGGGTCAAATT. After 48 
hours of transfection, target cells were transduced with 0.45 μm filtered viral supernatant 
and 8 μg/mL polybrene. Cells were selected 24 hours after media replacement with 2 μg /mL 
puromycin. For NSD3 overexpression in HT1080 cells, virus particles were produced by co-
transfection of 293T cells with pLenti CMV Hygro DEST (W117-1) (Addgene) or pLKO.1 
constructs, psPAX2 and pCMV-VSVg in a ratio of 5:3:2 by mass. After 48 hours of 
transfection, target cells were transduced with 0.45 μm filtered viral supernatant and 8 
μg/mL polybrene. The subsequent selection was carried out with 250 μg/mL hygromycin.
Mice.
ROSA26LSL-Pik3ca(H1047R), Col1a1LSL-Sox2, Cdkn2a/bLoxP/LoxP, Fgfr1LoxP/LoxP mice have 
been described before34-37. Reporter-tagged insertion with conditional potential 
Nsd3tm1a(EUCOMM) mouse strain originates from ES clone #HEPD0563-4-G02 obtained 
from European Mouse Mutant Archive repository38. The targeting vector includes the Neo-
LacZ cassette flanked by Frt sites and exon 4 sequence flanked by LoxP sites. Founder mice 
(Nsd3LacZ) were confirmed as germline-transmitted via crossbreeding with C57BL/6N wild-
type animals. Next, Nsd3LacZ mice were crossed with ROSA26FlpO deleter strain39 to 
generate conditional allele Nsd3LoxP/LoxP. LSL-Nsd3T1242A model was generated by 
knockin of the CAG-LoxP-Stop-LoxP-V5-mNsd3T1242A cDNA-polyA cassette into intron 1 
of ROSA26 using methods previously described40. Founder animals were identified by PCR 
followed by sequence analysis and germline transmission confirmed by crossbreeding with 
C57BL/6N wild-type animals. All mice were maintained in a mixed C57BL/6;129/Sv 
background, and we systematically used littermates as controls in all the experiments. 
Immunocompromised NSG mice (NOD.SCID-IL2Rg−/−) were utilized for tumor xenograft 
studies. All experiments were performed on balanced cohorts of male and female mice as 
our initial data did not indicate significant differences in disease progression or response to 
treatment between females or males. All animals were numbered and experiments were 
conducted in a blinded fashion. After data collection, genotypes were revealed and animals 
assigned to groups for analysis. For treatment experiments mice were randomized. None of 
the mice with the appropriate genotype were excluded from this study or used in any other 
experiments. Mice had not undergone prior treatment or procedures. All mice were co-
housed with littermates (2–5 per cage) in pathogen-free facility with standard controlled 
temperature of 72 °F, with a humidity of 30–70%, and a light cycle of 12 h on/12 h off set 
from 7am to 7pm and with unrestricted access to standard food and water under the 
supervision of veterinarians, in an AALAC-accredited animal facility at the University of 
Texas M.D. Anderson Cancer Center (MDACC). Mouse handling and care followed the NIH 
Guide for Care and Use of Laboratory Animals. All animal procedures followed the 
guidelines of and were approved by the MDACC Institutional Animal Care and Use 
Committee (IACUC protocol 00001636, PI: Mazur). Tumor size was measured using a 
digital caliper and tumor volume was calculated using the formula: Volume = (width)2 × 
length / 2 where length represents the largest tumor diameter and width represents the 
perpendicular tumor diameter. The endpoint was defined as the time at which a 
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progressively growing tumor reached 20 mm in its longest dimension as approved by the 
MDACC IACUC protocol (00001636, PI: Mazur). and in no experiments was this limit 
exceeded.
Lung Squamous Cell Carcinoma Mouse Models.
To generate tumors in the lungs of ROSA26LSL-Pik3ca(H1047R), Col1a1LSL-Sox2 Cdkn2a/
bLoxP/LoxP (PSC), ROSA26LSL-Pik3ca(H1047R); Col1a1LSL-Sox2; Cdkn2a/bLoxP/LoxP; 
Fgfr1LoxP/LoxP (PSCFGFR1-KO), ROSA26LSL-Pik3ca(H1047R); Col1a1LSL-Sox2; Cdkn2a/
bLoxP/LoxP; Nsd3LoxP/LoxP (PSCNSD3-KO), ROSA26LSL-Pik3ca(H1047R); Col1a1LSL-Sox2; 
Cdkn2a/bLoxP/LoxP; LSL-Nsd3T1242A (PSCN) mutant mice, we used replication-deficient 
adenoviruses expressing Cre-recombinase (Ad-Cre) as previously described41. Briefly, 8-
week old mice were anesthetized by continuous gaseous infusion of 2% isoflurane for at 
least 10 min using a veterinary anesthesia system (D19 Vaporizer, Vetland Medical). Ad-Cre 
was delivered to the lungs by intratracheal intubation. Prior to administration, Ad-Cre was 
precipitated with calcium phosphate to improve the delivery of Cre by increasing the 
efficiency of viral infection of the lung epithelium. Mice were treated with one dose of 5 × 
106 PFU of Ad-Cre (Baylor College of Medicine, Viral Vector Production Core). Mice were 
analyzed for tumor formation and progression at indicated times after infection.
Xenograft models.
Patient-derived xenografts (PDXs) were obtained from the NCI Patient-Derived Models 
Repository (PDMR), NCI-Frederick, Frederick National Laboratory for Cancer Research 
(997726-040-R, 692585-246-R, 417821-307-R) and the University of Texas M.D. Anderson 
Cancer Center repository. Briefly, surgically resected tumor specimens were obtained from 
deidentified patients with histologically confirmed LUSCs. All tumor specimens were 
collected after written patient consent and in accordance with the institutional review board-
approved protocols of the University of Texas M.D. Anderson Cancer Center (PA19-0435, 
PI: Mazur). Patient-derived xenograft tumors were generated and propagated by 
transplanting small tumor fragments isolated directly from surgical specimens 
subcutaneously into NSG mice as we established previously33. Genome-wide copy number 
analysis was performed for each PDX using an OncoScan CNV Assay Kit (Thermo Fisher 
Scientific) as previously described42. BioDiscovery’s Nexus Copy Number software was 
used to call CNAs using the default parameters. All data were analyzed and reported using 
the February 2009 NCBI human genome build 37.1 (hg19). NSD3 mutation analysis was 
performed by Sanger sequencing of exon 20 using genomic DNA and following primers 
NSD3ex20-F GACCGTATAATTGATGCCGGC, NSD3ex20-R 
CTGCAGGAATATCACAGAGAGC. For analysis of NSD3 knockdown growth, collected 
PDX tumors were minced using a razor blade and digested in collagenase digestion buffer at 
37°C for 1 hour. Cells were passed through 100 μm and 40 μm cell strainers and centrifuged 
for 1200 rpm for 5 min. Cells were incubated in RBC lysis buffer for 2 min and then 
resuspended in 6 mL of media and spun through 0.5 mL of serum layered on the bottom of 
the tube to remove cellular debris. Contaminating human or mouse hematopoietic and 
endothelial cells (CD45, Ter119, CD31) are depleted using biotin conjugated anti-mouse 
CD45, CD31 and Ter119 antibodies and separated on a MACS LS column using anti biotin 
microbeads. Next, the cells were transduced with lentivirus expressing sgRNA/Cas9 and 
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selected with puromycine for 72 hours. Next, the cells were collected, mixed with Matrigel 
(1:1) and transplanted to the flanks of NSG mice. For xenograft studies of human LUSC 
lines, transduced cells were cultured in 15- cm dishes trypsinized and singularized. The 
trypsin was washed with excess growth medium and the cells were counted. The cells were 
then resuspended in PBS and mixed with matrigel (1:1) at a density of 2 ×107 cells per ml 
and kept on ice until injection. Next, 100 μl of the cell suspension was injected 
subcutaneously onto the hind flanks of NSG mice. When tumors became palpable, they were 
calipered to monitor growth kinetics.
Tumorigenicity Assay in vitro and in vivo.
Immortalized human tracheobronchial epithelial (AALE) were described before23. AALE 
cells were maintained in Small Airway Epithelial Cell Growth Medium (SAGM) containing 
SAGM growth supplements (Lonza). AALE cells (1 × 107) were electroporated with 
PiggyBac transposon plasmids using NEPA21 electroporator (Nepagene) at the following 
settings: two poring pulses: 175 V, length 5.0 ms, interval 50.0 ms, decay rate 10%, positive 
polarity and five transfer pulses: 20 V, length 50.0 ms, interval 50.0 ms, decay rate 40%, at 
reversing polarities. For in vitro tumorigenic ability growth in soft agar was determined by 
plating 5 × 105 cells in triplicate. Colonies were counted 3 weeks after plating. For in vivo 
tumorigenic ability – ALLE cells were transplanted bilaterally under sub-renal capsule into 
immunocompromised NSG mice using protocol previously described 43. The cells 
resuspended in Matrigel (106 in 40 μl) were delivered through a blunted 25g needle attached 
to a silicone catheter. The catheter was advanced through the capsule incision to the cranial 
pole of the kidney and the cells discharged slowly from the catheter. For in vivo 
transformation assays AALE cells were electroporated with PiggyBac transposon plasmid 
expressing AkaLuc which catalyzes oxidation reaction of a substrate AkaLumine producing 
near-infrared bioluminescence which can penetrate most animal tissues 24,44. To monitor cell 
growth mice were injected i.p. with 3 μmol (1.0 mg) of AkaLumine-HCl (Sigma-Aldrich) in 
100 μl 0.9% NaCl. Immediately after substrate injection, bioluminescent images were 
acquired in an AMI HTX bioluminescence imaging system (Spectral Instruments Imaging). 
Imager settings were: Emission filter, open; field of view, 25 cm; f-stop 1.2; low binning 2 × 
2 and exposure time, 30 s. X-ray imaging camera settings were: field of view, 25 cm; low 
exposure and high resolution. Images were analyzed in the Aura software (Spectral 
Instruments Imaging) and quantified in radiance units of photons per second per square 
centimeter per steradian (photons/s/cm2/sr) and plotted as mean ± s.e.m..
Micro-Computed Tomography.
Micro Computed Tomography (μCT) scans were performed on indicated tumor mice at 90, 
120 and 150 days after Ad-Cre induction as previously described45. Briefly, mice were 
anesthetized by continuous gaseous infusion of 2% isoflurane for at least 10 min using a 
veterinary anesthesia system. The mice were intubated using a 20 gauge × 1 inch catheter 
and were transferred onto the bed of Explore Locus RS pre-clinical in vivo scanner (GE 
Medical Systems). The mice were mechanically ventilated in a small animal ventilator, and 
mCT images were captured at 80 kV and 450 microamperes. The X-ray source and CCD-
based detector gantry is rotated around the subject in roughly 1.0 degree increments. Each 
animal’s breathing was held at a pressure of 20 cm H20 during the 20 second acquisition. 
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The resulting raw data were reconstructed to a final image volume of 875 × 875 × 465 slices 
at 93 μm3 voxel dimensions. The images were cropped to display the lung region. The total 
chest space volume, including the heart, was selected using manual segmentation. An 
optimal threshold value was automatically determined using the function of the MicroView 
analysis software. Tumors formed at air space in the lung can be distinguished from other 
soft-tissue in a reconstructed 3D image of the higher voxels; therefore, the tumor nodule 
structure was selected using a combination of manual segmentation and semi-automated 
contouring of the optimal threshold value. These analyses were consistent between two 
independent operators and performed by a well-trained researcher in a blinded manner.
Histology and immunohistochemistry.
Tissue specimens were fixed in 4% buffered formalin for 24 hours and stored in 70% ethanol 
until paraffin embedding. 3 μm sections were stained with hematoxylin and eosin (HE) or 
used for immunohistochemical studies. Human tissue sections were collected in accordance 
with the institutional review board-approved protocols of the University of Texas M.D. 
Anderson Cancer Center (PA19-0435, PI: Mazur). Immunohistochemistry (IHC) was 
performed on formalin-fixed, paraffin embedded mouse and human tissue sections using a 
biotin-avidin method as described before41. The following antibodies were used (at the 
indicated dilutions): cleaved Caspase 3 (CST #9664, 1:100), H3K36me2 (CST #2901, 
1:2000), Ki67 (BD Bioscience #550609, 1:1,000), KRT5 (CST #71536, 1:1000), NSD3 
(described above), p63 (Abcam, #ab124762, 1:500) and TTF1 (Abcam #ab76013, 1:500). 
Sections were developed with DAB and counterstained with hematoxylin. Pictures were 
taken using a PreciPoint M8 microscope equipped with the PointView software. Analysis of 
the tumor area and IHC analysis was done using ImageJ software. Quantification of NSD3 
IHC chromogen intensity was performed by measuring the reciprocal intensity of the 
chromogen stain as previously describe46. Briefly, standard RGB color images acquired 
from bright field microscopy have a maximum intensity of value 250 (represented by white, 
unstained areas) as measured by the standard intensity function in the open source ImageJ 
Fiji software. We subtracted the intensity of a stained tissue sample from 250, thereby 
deriving a reciprocal intensity that is directly proportional to the amount of chromogen 
present.
Microscale thermophoresis (MST).
Binding affinities (Kd) were determined from three independent experiments using Cy5-
labeled dsDNA (147bp or 187bp)-nucleosomes at concentration 100 nM mixed in 1:1 
volume ratio with appropriate NSD3SET or NSD3SET-T1232A proteins at 16 different 
concentrations. Buffer conditions were 50 mM TRIS/TRIS-HCl, at pH 7.5, 150 mM NaCl, 1 
mM TCEP. Binding was quantified by microscale thermophoresis on a Monolith 
NT.115Pico instrument with all measurements performed at room temperature.
ITC measurements.
SAM [S-(5′-Adenosyl)-L-methionine chloride dihydrochloride; Merck A7007] was 
dissolved in 50 mM TRIS/TRIS·HCl pH = 7.5, 150 mM NaCl, 1 mM TCEP, and the pH was 
checked. SAM was used at 150 μM concentration, NSD3SET or NSD3SET-T1232A domains at 
100-125 μM, and ITC measurements were performed in a MicroCal PEAQ-ITC instrument 
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(Malvern Panalytical) at 20°C with 55 injections of 0.7 μL of SAM. Data were analyzed 
using ITC software to obtain Kds and stoichiometry.
Thermal stability essays.
The SET-domain stability in NSD3SET, NSD3SET-T1232A or NSD3SET-T1232A/V1243A was 
studied by protein thermal stability assay. The proteins (at 1mg/ml) were incubated with 
SYPRO Orange (ThermoFisher, cat. No S6651) for 1min at 25 °C, containing 50 mM TRIS/
TRIS·HCl, 150 mM NaCl, pH 7.5, and 1 mM TCEP. The stability essay was repeated for 
each protein 8 times and resulting temperatures were averaged. Fluorescence measurements 
(excitation, 450-490 nm; detection, 560-580 nm; BioRad CFX96 Touch Real-Time PCR 
Detection System) were collected following 30s incubation steps, respectively, with each 
step including a rise of 0.5 degree starting 15 °C to finally 95 °C.
NMR spectroscopy.
All NMR experiments were carried out at 25°C on NSD3SET or NSD3SET-T1232A samples at 
200-370 μM in buffer of 50 mM TRIS/TRIS·HCl, pH = 7.5, 150 mM NaCl, and 1 mM 
TCEP with 1% / 99% (v/v) D2O/H2O, and a twofold molar excess of SAM, using Bruker 
NEO 700 and 950 MHz spectrometers with inverse-detected TCI cryogenic probes. Nearly 
complete sequence specific backbone resonance assignments (>95% for NSD3SET or 
NSD3SET-T1232A) were achieved on double labeled 200-370 μM U-[13C,15N] NSD3SET or 
NSD3SET-T1232A samples using transverse relaxation optimized spectroscopy, TROSY-based 
triple resonance three-dimensional (3D) experiments of HNCO, HNcaCO, HNCA, 
HNcoCA, HNCACB, CBCAcoNH with further support from TROSY-version of 3D 15N-
edited NOESY (100 ms mixing time) recorded on 370 μM U-[15N] samples47-49. Data were 
processed using Topspin 4.07 program and analyzed with the program SPARKY (Goddard 
and Kneller) and CARA (cara.nmr.ch). NSD3SET and NSD3SET-T1232A backbone torsion 
angles were determined with Talos-N software50. The mobility of the protein backbone was 
studied by NMR 15N spin relaxation measurements using TROSY-based 15N[1H] nuclear 
Overhauser effect (NOE) experiments optimized for high-molecular weight proteins on 370 
μM uniformly labeled U-[15N] NSD3SET or NSD3SET-T1232A preparations containing 
variants51. The recycle delay for 15N[1H] NOE was 10 s and 4 s of 1H saturation. The errors 
of 15N[1H] NOE were determined based on the following equation: dNOEi = ∣NOEi∣·
[(1/SNRNOE,i)2+(1/SNRnoNOE,i)2]0.5, where SNR is signal to noise ratio for the experiment 
with (noNOE) and without saturation (NOE) and ∣NOEi∣ the intensity ratio of saturated and 
non-saturated signal. The chemical shift perturbation of 1H/15N resonances was determined 
with the equation: CSPi = [(ΔδH,i)2+0.25·(ΔδN,i)2]0.552, where ΔδH,i and ΔδN,i are detected 
chemical shift changes of proton and nitrogen, respectively.
Docking of H3 peptide to NSD3SET domain and modelling the NSD3SET auto-inhibited 
state.
The HADDOCK2.4 program53 was used in order to dock a H3.1 peptide (residues 29-42) 
into the binding cleft of NSD3SET. The starting structure for the NSD3SET domain was the 
6CEN X-ray structure54 with the G1267-N1268 residues modelled which are lacking from the 
experimental electron density in the SwissModel55. The structure of NSD3SET (PDB id: 
6CEN) is optimal as template for this approach as it is complexed with a peptidic inhibitor 
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and its backbone is overlapping nearly completely with the analogical residues from 
H3.3K36M peptide (residues 29-42) in the SETD2SET:H3.3K36M complex56,57. The 
starting peptide pose for H3.1 peptide for NSD3SET was taken from SETD2SET:H3.3K36M 
model, with M36 modified to K36 and H3.3 into H3.1 (S32 to A32) and used to define 
ambiguous interaction restraints (AIRs) driving the docking process. Remaining parameters 
were treated according to standard docking protocol53. The NSD3SET with the regulatory 
loop in the closed conformation (auto-inhibited state) was modelled using SwissModel55and 
the crystal structure of NSD2SET [PDB id: 5LSU:A; fragment 983-1203]58 as the template 
(sequence identity 79.2%, similarity 87.3%).
RNA-seq and Real-Time PCR Gene Expression Analysis.
RNA samples were extracted from cells using TRIzol reagent (Life Technologies), the RNA-
seq libraries were constructed and sequenced in BGI. Or the RNA samples were reverse 
transcribed into cDNA using the SuperScript IV First Strand Synthesis System (Invitrogen). 
Quantitative real-time PCR analysis was performed on a Roche LightCycler 480 using 
SYBR Green Master Mix (Applied Biosystems) following the manufacturer’s manual. The 
expression of each gene was normalized to actin (Actb). The primer sequences are listed 
below: Irgm1-qPCR-F AGCATCTTTGTGACTGGGGA, Irgm1-qPCR-R 
TAAGTCCCACAGCACCACAT, Prkaa2-qPCR-F TACATCTGCAAACATGGGCG, 
Prkaa2-qPCR-R TCTTAGCGTTCATCTGGGCA, Myc-qPCR-F 
CCTTCTCTCCTTCCTCGGAC, Myc-qPCR-R TGCCTCTTCTCCACAGACAC, Actb-
qPCR-F ACTGGGACGACATGGAGAAG, Actb-qPCR-R 
GTCTCCGGAGTCCATCACAA.
RNA-seq analysis.
The PSCN cells ±NSD3 depletion RNA-seq reads were aligned to mouse genome mm10 by 
HISAT2 (ccb.jhu.edu/software/hisat2)59. Then the transcriptomes were annotated to 
GENCODE M23 (gencodegenes.org)60 by FeatureCounts (2.0.0) 61. Differentially expressed 
genes (DEGs) were detected by DESeq2 package from Bioconductor (bioconductor.org/
packages/release/bioc/html/DESeq2)62 using likelihood ratio test (LRT, adjusted P-value < 
0.001) or Wald test. The expression levels of genes were normalized and log2-transformed, 
and the variances-stabling transformation were implemented. Bioconductor package 
EnhancedVolcano (bioconductor.org/packages/release/bioc/html/EnhancedVolcano, 1.8.0) 
was used to generate the volcano plot. Hierarchical clustering was implemented to cluster 
the trends of the DEGs. The functional enrichment analyses were implemented by GSEA 
(gsea-msigdb.org/gsea, 4.0.0)63 and the Bioconductor package GeneAnswers 
(bioconductor.org/packages/release/bioc/html/GeneAnswers, 2.32.0). The comparisons of 
expression levels of DEGs and all genes were implemented by two-sided robust t-test, and 
the trim level was 0.1.
TCGA data set analysis.
Lung squamous cell carcinoma patient TCGA data (Project ID: TCGA-LUSC, dbGaP Study 
Accession: phs000178)64 was analyzed using cBioPortal 65,66 to identify copy number and 
mRNA expression. Copy number amplification datasets within the portal were generated by 
the Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm identifying 
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significantly altered regions of amplification or deletion across sets of patients. GISTIC-
derived copy number analysis indicate copy-number level per gene, in which 1 and 2 
indicates amplification. Basal-normalized transcript expression data (z score) used for this 
analysis were RNA Seq V2 RSEM.
CUT&RUN.
This assay was performed as described previously with modifications67 and using the 
H3K36me2 and H3K27me3 antibodies noted above. Buffer exchange was performed by 
centrifugation at 4 °C, 600g for 5 minutes. After the addition of concanavalin A beads, the 
buffer exchange was performed with a magnetic stand, allowing at least 5 minutes for the 
beads to completely bind to the magnet. Cells were harvested into a single cell suspension, 
counted, washed once with ice-cold PBS and resuspended with ice-cold Nuclear Extraction 
(NE) buffer to a final concentration of 1 ×107 cells/mL. After 10 minutes on ice, cells were 
washed with Wash Buffer (WB) and resuspended in WB at a final concentration of 5 × 106 
cells/mL. Efficient nuclear extraction was confirmed by Trypan Blue staining. In case of 
presence of nuclear aggregates, suspension was filtered through a 40 μm strainer before 
proceeding to next step. Concanavalin A beads were equilibrated in ice-cold binding buffer 
and mixed with the isolated nuclei (10 μl bead slurry per 5 × 105 cells). The nuclei-beads 
mixture was incubated for 10 minutes rotating at 4°C. Successful nuclei-bead binding was 
confirmed with Trypan Blue staining. Beads-coated nuclei were resuspended in WB at a 
final concentration of 5 × 106 cells/mL and 100 μL were aliquoted into each sample tube. 
While gently vortexing, 100 μL of 2× primary antibody mix was added to the corresponding 
sample tube. Tube samples were mixed and incubated in rotation overnight at 4°C. Next day, 
nuclei were washed twice with 1 mL of ice-cold WB and resuspended in 25 μL of ice-cold 
WB. While gently vortexing, 25 μL of 2× pAG-MNase mix (EpiCypher, Inc. catalog # 
15-1016) was added to each tube and samples were incubated for 1 hour at 4°C. Nuclei were 
washed twice with WB and resuspended in 150 μL of ice cold WB. While gently vortexing, 
3 μL of pre-chilled 100 μM CaCl2 were added and after briefly flicking to mix, tubes were 
incubated for 30 minutes in a 0 °C water bath. After 30 minutes, the MNase was inactivated 
by adding 150 μL of 2× STOP buffer. To isolate the digested DNA though diffusion, samples 
were incubated 20 minutes at 37 °C with no shaking. Samples were centrifuged at 16,000 g 
for 5 minutes at 4°C and the resulting supernatant was treated with 3 μL of 10% SDS and 
2.5 μL of 20 mg/mL proteinase K at 65 °C for 1 hour to overnight without shaking. DNA 
was purified with Qiagen MinElute PCR purification kit. Sequencing libraries were 
constructed using NEBNext Ultra II DNA Library Prep Kit for Illumina (NEB E7645L) 
following the manufacturer’s manual. The libraries were sequenced at BGI.
CUT&RUN sequencing data analysis.
The CUT&RUN sequencing data were aligned by Cut&RunTools (bitbucket.org/qzhudfci/
cutruntools/src/master/, version: 49ddd24)68. The reads were trimmed by Trimmomatic69, 
then aligned to the mouse genome mm10 by Bowtie2 (bowtie-bio.sourceforge.net/
bowtie2)70. The duplicate reads at same locations were removed by MarkDuplicates of 
Picard package (broadinstitute.github.io/picard, 2.23.8). The enrichment density of different 
samples were normalized to read counts per million mapped reads and same scale of the 
gene body by ngs.plot (github.com/shenlab-sinai/ngsplot, 2.63)71. Enrichment density was 
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normalized by the spike-ins and then the average profile figures of the gene body regions 
were generated by ngs.plot. Gene body regions were scanned for DEGs and genome-wide 
genes, and the peak intensity was extracted for PSCN cells with control knockdown over 
NSD3 knockdown (ΔPeaks), the differences between them calculated, and compared to the 
distribution of ΔPeaks of DEGs and the genome-wide genes with two-sided robust t-test at 
the trim level 0.1. The intergenic region annotation was generated by Complement of 
BedTools72, and then the average profile of the intergenic regions was visualized by 
ngs.plot.
ChIP-qPCR.
ChIP assays were performed as described25. Purified DNA was subject to quantitative real-
time PCR analysis. Purified ChIP DNA was analyzed on LightCycler 480 (Roche) using 
SYBR Green Master Mix (Applied Biosystems) following the manufacturer’s manual. All 
samples were normalized to input as control. The primer sequences are listed below:
Irgm1-p1 F: GTTGGGGTTGGAGTTGTGTC, Irgm1-p1 R: 
TTGCTGGGTCTGGAGGTTAG, Irgm1-p2 F: CTGAGCTGGGTGTATAGGCA, Irgm1-p2 
R: CTTGTCTGTGTACCCCGTCT, Irgm1-p3 F: TAAGTCCCACAGCACCACAT, Irgm1-p3 
R: AGCATCTTTGTGACTGGGGA, Prkaa2-p1 F: GTGCCAGTTTCTTAGCCCAG, 
Prkaa2-p1 R: ACACATGGTCAGACTCAGCA, Prkaa2-p2 F: 
TTTGTTTCACCAGCCCCTTG, Prkaa2-p2 R: AACGGACTGTAGCCTGGAAA, Prkaa2-
p3 F: GACACACCTCCAAGCATGTC, Prkaa2-p3 R: GCTCTGTTCACATCCTCCCT, Btg2 
F: GAGTGGTATGAAAGGCGCAG, Btg2 R: GGAGACTGGAGAGGAAACCC, Gadd45g 
F: CTGGGAATCTTTACCTGCGC, Gadd45g R: AGACCACTACCAGACAAGGC.
Statistics and Reproducibility.
All statistics used in this study are described when used in the appropriate section. For all 
the Western blot and autoradiography results, the reported data were reproduced three 
independent times (or more as indicated) and representative data are shown.
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Extended Figure 1. Characterization of genetic drivers of LUSC tumorigenesis.
a, Genetic alterations and mRNA expression of genes in the 8p11-12 amplification genomic 
region of chromosome 8 from the 85 8p11-12 amplified human LUSC specimens in the 
TCGA dataset. b, Genetic alterations and mRNA expression of NSD3, FGFR1, PIK3CA, 
PTEN, SOX2, CDKN2A, CDKN2B from all 464 of the human LUSC specimens in the 
TCGA dataset (ID: phs000178) analyzed using cBioPortal.
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Extended Figure 2. NSD3 but not FGFR1 depletion inhibits LUSC tumorigenesis in vivo.
a, Western blot analysis with the indicated antibodies of whole-cell lysates from H520 cells 
expressing sgControl or sgNSD3. The bands representing NSD3 and NSD3Short are 
indicated. Tubulin was used as a loading control. b, Western blot analysis with the indicated 
antibodies of whole-cell lysates from H520 cells expressing sgControl or sgFGFR1. Tubulin 
was used as a loading control. c, Real-time (RT) qPCR analysis of PLPP5 mRNA expression 
in H520 cells expressing sgControl or sgPLPP5. We note that several commercial antibodies 
against PLPP5 were tested but we could not detect any reproducible band close to the 
correct size (data not shown). The RT-qPCR data were normalized to Actb and presented as 
fold change relative to the sgControl sample. Error bars represent mean ± s.d. from three 
independent experiments. P value determined by two-tailed unpaired t-test. d, Treatment of 
the 8p11AMP-positive H520 LUSC cell line with sgRNAs targeting the 8p11-amplified 
region does not cause an increase in phosphorylated H2AX (γH2AX). Western blot analysis 
with the indicated antibodies of H520 cells expressing Cas9 and the indicated sgRNAs. 
DNA damage-induced by hydroxyurea (HU) treatment was used as a positive control, H3 
was used as a loading control. e, Depletion of NSD3, but not depletion of FGFR1 or PLPP5, 
attenuates xenograft growth of the 8p11AMP H520 LUSC cells. Tumor volume 
quantification of the indicated H520 xenografts generated in immunocompromised mice (n 
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= 5 mice, for each treatment group). P values indicated determined by two-way ANOVA 
with Tukey’s post hoc test. Data are represented as mean ± s.e.m. Data showing sgControl, 
sgNSD3 and sgFGFR1 are the same as from Figure 1b. f, Representative HE-stained 
sections and IHC staining of lung tissue from PSC mouse model lung tumor showing key 
diagnostic histological features of LUSC including positive staining for keratin and p63 and 
negative staining for TTF1 (representative of n = 8 samples for each group). Human LUSC 
samples are shown for comparison (representative of n = 8 samples for each group). Scale 
bars, 50 μm. g, Increased expression of NSD3 in lungs tracks with tumor progression. IHC 
analysis of NSD3 levels in wild type lung and tumor biopsies collected from the PSC model 
at 150 days and at the clinical endpoint when animals develop significant morbidity 
(representative of n = 8 samples for each group). Scale bars, 50 μm. h, Quantification of 
NSD3 levels in tumor biopsies as in (g) within tumor areas that have high-, low-intensity or 
negative staining for chromogen. Data are represented as mean ± s.e.m. i, NSD3 mRNA 
overexpression is common (~60%) and not limited to 8p11-12 amplified tumors. Genetic 
alterations and mRNA expression of the indicated genes in human LUSC patient samples 
from the TCGA dataset showing frequency of overexpression and alternations in NSD3 and 
known driver mutations PIK3CA, PTEN, SOX2, CDKN2A, CDKN2B. j, Representative 
HE-stained sections and IHC staining of lung tissue from PSC (control), PSCFGFR1-KO and 
PSCNSD3-KO mutant mice, (representative of n = 8 mice for each experimental group). Scale 
bars, 50 μm; arrowheads, positive cleaved Caspase 3 cells. k, l, Quantification of Ki67 
(Ki67+ positive cells) a marker of proliferation (k) and cleaved Caspase 3 (cl. Caspase 3+ 
positive cells) a marker of apoptosis (l) in samples as in (j). In k, l and in all subsequent box 
plots, the line indicates the median, the box marks the 75th and 25th percentiles and the 
whiskers indicate the minimum and maximum values. All data points are shown. P values 
indicated determined by one-way ANOVA with Tukey’s post hoc test (k, l).
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Extended Figure 3. Identification of the cancer-associated NSD3T1232A variant as a gain of 
function variant.
a, Schematic diagram of the distribution of the different NSD3 candidate mutants tested in 
(b). b, In vitro methylation assay as in Figure 2b on rNuc with recombinant wild-type 
NSD3SET or the indicated mutants (1-35) with non-radiolabeled SAM (the T1232A mutant 
is indicated in red). For each screening panel set, the top of the panel shows the Western blot 
and the bottom panel, Coomassie blue stain of the NSD3 proteins. c, Schematic diagram of 
NSD3 fragments used in this study. d, In vitro methylation reactions with rNucs and 
different concentrations of recombinant wild-type NSD3SET or NSD3SET-T1232A with 3H-
SAM. Methylation intensity was measured by liquid scintillation counting. Error bars 
represent mean ± s.d. from three independent experiments. e, Western blot analysis with the 
indicated antibodies of whole cell extracts from NSD2-deficient HT1080 cells (to deplete 
H3K36me2 compared to control HT1080 cells (lanes 1 and 2)) overexpressing the indicated 
NSD3 variants. Total H3 was used as a loading control. f, Methylation assays as in Figure 2b 
with rNuc with linker DNA (187 bp) and increasing concentrations of enzyme as indicated. 
Western blot shows H3K36me2 generation, H3 is shown as a loading control. Bottom panel, 
Coomassie blue stain of NSD3 proteins.
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Extended Figure 4. Biophysical characterization of T1232A substitution on the NSD3SET 
domain.
a, Kd values with corresponding errors being s.d. are shown for binding studies of NSD3SET 
and NSD3SET-T1232A to recombinant nucleosomes (rNuc) reconstituted on 147bp and 187bp 
601 Widom DNA as indicated (determined by microscale thermophoresis (MST)) and the 
cofactor SAM (determined by ITC) (see Supplementary Table 1; see Methods). Error bars 
represent mean ± s.d. from three independent experiments. b, The topology of NSD3SET 
domain segments of Pre-SET (white-gray), SET (cyan), Post-SET (dark gray) and regulatory 
loop (magenta) marked onto the ribbon representations of existing NSD3SET domain crystal 
structures (PDB 5UPD, 6CEN). The missing residues in the tip of the regulatory loop, not 
modelled into the electron densities, are denoted with dotted lines. The zinc(II) ions are 
depicted as gray spheres, SAM cofactor with sticks. Residues T1232 and V1243 are marked 
with their side-chains. Bottom panel: Schematic representation of the primary sequence with 
indicated domains and the location of the T1232A substitution. c, The overlay of the 2D [1H,
15N] TROSY-HSQC (Transverse Relaxation Optimized SpectroscopY - Heteronuclear 
Single Quantum Coherence) spectra of 250 μM U-[15N] NSD3SET wild-type (dark gray) 
and NSD3SET-T1232A (magenta) at pH 7.5 and 25°C. The 1H/15N backbone amide cross-
peaks of T1232 in NSD3SET wild-type and A1232 of NSD3SETT1232A mutant are marked. d, 
The backbone amide chemical shift perturbations (CSPi = [(ΔδH,i)2+0.25·(ΔδN,i)2]0.5) 
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between NSD3SET and NSD3SET-T1232A are mapped onto the ribbon representations of 
protein structures; left: the NSD3SET with regulatory loop in closed (PDB 5UPD), center: in 
open (based on the NSD2SET crystal structure (PDB 5LSU) modelled with SwissModel) and 
right: the open conformation with the H3.1 A29-R42 substrate docked (see Methods). The 
T1232 and V1243 residues are marked with their side-chains. Residues are colored as 
follows: 0.03 ≤ CSPi < 0.05 (yellow), 0.05 ≤ CSPi < 0.11 (light orange), 0.11 ≤ CSPi < 0.75 
ppm (orange), CSPi > 4.60 (red), prolines and residues missing amide assignments are 
marked gray. e, The overlay of NSD3SET domains with the regulatory loop in open and 
closed conformations. The open state is the crystal structure of NSD3SET, while the closed 
state is based on the NSD2SET crystal structure (PDB 5LSU) modelled with SwissModel. 
The protein sequence graph and coloring as in 4h. f, The projections of 2D TROSY-type 
heteronuclear {1H}-15N nuclear Overhauser effect (NOE) experiments collected for 370 μM 
U-[15N] NSD3SET wild-type (left panel) and NSD3SET-T1232A (right panel) at pH 7.5 and 
25°C with several residues marked. (Experimental details in Methods). The higher NOE 
ratio value the more rigid the N-H vector, meaning less dynamic motion, whereas the lower 
value means more dynamic, indicative of less restricted motions. The tryptophan imidazole 
side-chain 1H/15N correlations are also detected in this experiment, Hε1/Nε1 from W1235 
and W1157. g, The observed changes in {1H}-15N NOE values (ΔNOEi) reporting on ps-ns 
polypeptide main-chain mobility differences between NSD3SET and NSD3SET-T1232A are 
plotted on the 3D static structures of NSD3SET (PDB: 6CEN, left column represented as 
protein surface, middle column ribbon with H3 peptide, right column ribbon with no 
substrate). Key features are indicated. The light blue to dark blue indicates the decreased fast 
dynamics after T1232A substitution, and yellow to red increased dynamics on ps-ns time 
scale. h, The T1232A substitution enhances the mobility of the regulatory loop. The 
observed changes in heteronuclear {1H}-15N nuclear Overhauser effect (NOE) mapped on 
the ribbon representations of the open and closed states of the regulatory loop within the 
NSD3SET and in Figure 2e. The structures are the same as in (e). i, Methylation assays as in 
Figure 2a with rNuc(187bp) and the indicated NSD3 variants.
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Extended Figure 5. Generation of PSCN LUSC mouse model and NSD3 coordination of an 
oncogenic gene expression program in LUSC.
a, Alignment of NSD3 human and mouse residues spanning human T1232 indicates that 
human NSD3 T1232 corresponds with murine NSD3 T1242. b, Schematic of the LSL-V5-
Nsd3T1242A conditional allele. In the presence of Cre recombinase, a translational stop 
cassette flanked by LoxP recombination sites is deleted to enable V5-Nsd3T1242A 
expression. P1 and P2 indicate location of genotyping primers. c, Confirmation of successful 
generation of LSL-Nsd3T1242A allele by PCR (P1+P2+P3 primers) on DNA isolated from 
mouse tail biopsies from indicated mouse genotypes, expected products sizes are marked 
(upper panel). d, Western blots with the indicated antibodies (V5 antibody detects V5-tagged 
NSD3T1242A) of lysates from LSL-V5-Nsd3T1242A lung fibroblast transduced ex vivo with 
Ad-Cre or vehicle (control). Actin is shown as a loading control. e, Left panel: Sanger 
sequencing confirmation Nsd3T1242A mutation is present in generated conditional LSL-V5-
Nsd3T1242A mutant mouse. Wild-type NSD3 sequence from control animals is shown on the 
right panel. f, Representative HE-stained and IHC staining with indicated antibodies of lung 
tissue sections from PSC and PSCN mutant mice, (representative of n = 8 mice for each 
group). Scale bars, 50 μm; arrowheads, positive cleaved Caspase 3 cells. g, Quantification of 
cleaved Caspase 3 (cl. Caspase 3+ positive cells) a marker of apoptosis in samples as in (f). P 
values indicated determined by two-tailed unpaired t-test. h, Western blots with indicated 
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antibodies of whole-cell lysates from PSCC or two different PSCN cell line. Total H3 was 
used as a loading control. i, Volcano plot of RNA-seq comparison between PSCN and PSC 
tumor biopsies (three independent biological replicates for each condition) results in higher 
expression of 891 genes shown in red (fold change log2 ≤ −0.5 and P < 0.05 by Wald test) 
and decreasing expression of 1839 genes shown in green (fold change log2 ≥ 0.5 and P < 
0.05 by Wald test). False discovery rate (FDR) values are provided. j, Volcano plot of RNA-
seq comparison of PSCN cells ± sgNSD3 (three biological replicates for each condition) 
causes decreasing expression of 234 genes shown in red (adjusted P < 0.001 by likelihood 
ratio test) and increasing expression of 229 genes shown in green (adjusted P < 0.001 by 
likelihood ratio test). False discovery rate (FDR) values are provided. k, Top hallmark gene 
sets identified in the GSEA analysis of datasets from (i-j) shows high overlap. Normalized 
enrichment scores (NES) provided (detailed statistics description in Methods). l, 
Reconstitution of NSD3-deficient PSCN cells with NSD3 and derivatives. Western blot 
analysis with the indicated antibodies of PSCN whole cell lysates ± sgNSD3 and 
complemented with the indicated CRISPR-resistant NSD3 derivatives. H3 and tubulin were 
used as loading controls. m, Quantitative real-time (RT)-PCR analysis of the transcript levels 
of the indicated genes in the cells as described in (l). The RT-qPCR data for each gene were 
normalized to Actb and presented as fold change relative to the sgControl sample. Error bars 
represent mean ± s.d. from three independent experiments. P values indicated determined by 
one-way ANOVA with Tukey’s post hoc test.
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Extended Figure 6. NSD3T1242A-mediated H3K36me2 in LUSC oncogenic reprogramming.
a, Independent CUT&RUN replicate for H3K36me2 as in Figure 3i. b, Normalized gene 
expression levels from the indicated groups from PSCN cell line RNA-seq datasets. dDEG 
(downregulated DEGs) and uDEG (upregulated DEGs) from Extended Data Fig. 5j, and all 
genes. P values indicated determined by two-tailed robust t-test (detailed statistics 
description in Methods). dDEG n = 234, uDEG n = 229, all genes n = 16091. Boxes: 25th to 
75th percentile, whiskers: min. to max., center: median. c, CUT&RUN profile for 
H3K36me2 and H3K27me3 in PSCN cells ± sgNSD3 over average of intergenic regions on 
a genome-wide scale. d, CUT&RUN profile for a monoclonal IgG (against GFP) as in 
Figure 3i for all genes and dDEG as indicated in PSCN cells ±sgNSD3 is shown as a 
negative control. e, Genome browser view of CUT&RUN signals for H3K36me2 and 
H3K27me3 on the indicated genes and conditions. Arrow indicates the direction of gene 
transcription. f, Loss of occupancy of NSD3T1242A and H3K36me2 at the indicated NSD3-
target genes (Irgm1 and Prkaa2) upon NSD3 depletion. Btg2 and Gadd45g are not NSD3-
target genes and shown as control regions that do not change in response to NSD3 depletion. 
ChIP-qPCR analysis of V5-NSD3T1242A (top panel) and H3K36me2 (bottom panel) in the 
body of the indicated genes. The data were plotted as percent enrichment relative to input. 
Error bars represent mean ± s.d. from three independent experiments. P values indicated 
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determined by two-tailed unpaired t-test. g, NSD3T1242A and H3K36me2 occupy the 
promoter and gene body regions of target genes Irgm1 and Prkaa2. Top panel, schematic of 
general gene structure and site of primers for Irgm1 (left panel) and Prkaa2 (right panel) 
gene loci. ChIP-qPCR analysis of V5-NSD3T1242A (left panel) and H3K36me2 (right panel) 
in promoter (p1), gene body (p2) and transcription end site (TES; p3) regions of target 
genes. TSS: transcription start site. The data were plotted as percent enrichment relative to 
input. Error bars represent mean ± s.d. from three independent experiments. P values 
indicated determined by two-tailed unpaired t-test. h, ChIP-qPCR analysis of NSD3T1242A 
(left panel) and H3K36me2 (right panel) occupancy at the gene body regions of Irgm1 and 
Prkaa2 gene loci in reconstituted cells as described in Extended Data Fig. 5l. The 
enrichment was normalized to the sgControl sample and presented as fold change relative to 
the sgControl sample. Error bars represent mean ± s.d. from three independent experiments. 
P values indicated determined by one-way ANOVA with Tukey’s post hoc test.
Extended Figure 7. NSD3 depletion attenuates growth of 8p11-amplified and NSD3-
overexpressing human LUSC cell lines and ectopic expression of NSD3 cooperates with SOX2 to 
transform tracheobronchial epithelial cells.
a, Genetic alterations and mRNA expression of LUSC-associated genes in human LUSC cell 
lines used in this study. b, NSD3 depletion by CRISPR/Cas9 attenuates xenograft tumor 
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growth of 8p11AMP and NSD3-overexpressing LUSC cell lines. Upper panel: Tumor volume 
quantification of human LUSC cell line xenografts described in (Figure 4a and Extended 
Data Fig 7a) treated with sgControl or sgNSD3 as indicated and grown in 
immunocompromised mice at 28 days after implantation (n = 5 mice, for each treatment 
group). P values indicated determined by one-way ANOVA with Tukey’s post hoc test. Data 
are represented as mean ± s.e.m. Lower panel: Western blot analysis with the indicated 
antibodies of whole cell lysates from cells in upper panel. γH2AX levels are shown to assess 
whether sgNSD3 expression induces non-specific DNA damage. H3 and Actin are used as 
loading controls. (upper panel). c, NSD3 depletion by shRNA attenuates xenograft tumor 
growth of 8p11AMP positive LUSC cell lines. Upper panel: Tumor volume quantification of 
the indicated 8p11AMP-positive and two control 8p11AMP-negative human LUSC cell line 
xenografts described as in (a) treated with shControl or shNSD3 as indicated and grown in 
immunocompromised mice at 28 days after implantation (n = 5 mice, for each treatment 
group). P values indicated determined by one-way ANOVA with Tukey’s post hoc test. Data 
are represented as mean ± s.e.m. Lower panel: Western blot analysis with the indicated 
antibodies of whole cell lysates from cells in upper panel. Actin is used as a loading control. 
d, NSD3-deficient H520 cells reconstituted with the indicated V5-tagged CRISPR-resistant 
NSD3 derivatives: NSD3T1232A (NSD3TA) NSD3T1232A/Y1174A (NSD3TA/YA). Western blots 
of H520 lysates with indicated antibodies H3 and tubulin were used as loading controls (see 
Figure 4b). e, Western blots of whole cell lysate of AALE cells used in transformation 
assays for Figure 4c with ectopic expression of SOX2 and the indicated V5-tagged 
constructs (NSD3WT, NSD3TA, NSD3YA, NSD3TA/YA, NSD3Short or FOXE1). f, 
Quantification of soft agar colony formation for AALE tracheobronchial epithelial cells with 
ectopic expression of SOX2 and NSD3WT, NSD3TA, NSD3YA, NSD3TA/YA, NSD3Short or 
FOXE1 as in (e). Data are represented as mean ± s.e.m. of three technical replicates in two 
independent experiments. g, Representative soft-agar images from AALE transformation 
assays in (f). h, In vivo AALE transformation assay images from Figure 4c. Optical overlay 
of bioluminescent signal with X-ray image of mice grafted under the renal capsule with 
AALE cells expressing plasmids as in (e) and AkaLuc after substrate (AkaLumine-HCl; see 
Methods) administration (n = 5 for each condition). The color bar indicates the total 
bioluminescence radiance (photons/s/cm2/sr).
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Extended Figure 8. Genomic characterization of patient-derived xenografts (PDX) from primary 
LUSC.
a, Distribution of whole-genome copy number alterations in LUSC PDXs utilized in this 
study by OncoScan (detailed description in Methods). Green lines: 3p11 amplification 
(including PIK3CA and SOX2); red lines: marks, 8p11-12 (e.g. NSD3 and FGFR1 as 
shown); blue lines: biallelic deletion in 9p21.3 (including CDKN2A/B). b, Sanger 
sequencing analysis of NSD3 SET domain mutation status in collection of 37 LUSC PDX 
identified NSD3T1232A mutation in one of the PDX samples (PDXT1232A) and Nsd3 
wildtype in other analyzed PDXs.
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Extended Figure 9. NSD3-dependency renders PDXs from LUSC patients therapeutically 
vulnerable to BETi.
a-c, Tumor volume quantification of PDXCTR-1 (a), PDXCTR-2 (b) and PDXAMP-2 (c) 
growing in immunocompromised mice (n = 5 mice, for each treatment group). Western blots 
with the indicated antibodies of lysates from the PDX ± sgNSD3 is shown. Actin is shown 
as a loading control. d, BRD4 interacts with NSD3 in PSCN cells. Left panel: Western blot 
of whole cell lysates from PSCN cells ± sgNSD3 to show the relative position of NSD3 and 
NSD3Short in PSCN cells. Tubulin used as a loading control. Right panel: BRD4 interacts 
with both NSD3 and NSD3Short isoforms in PSCN cells. Co-immunoprecipitation (IP) 
experiments in PSCN cells with indicated antibodies for IPs and western analyses. Input, 
PSCN cell nuclear extract. e, Proliferation assay of PSCC and PSCN treated with vehicle 
control or 20nM AZD5153 (BETi). Data represent mean ± s.e.m. of three technical 
replicates in two independent experiments. f, Treatment of PSCN cells with the BETi JQ1 
inhibits expression of the indicated NSD3 target genes. Real-time (RT) qPCR analysis of the 
indicated mRNAs from PSCN cells treated with DMSO or 100nM of JQ1. The RT-qPCR 
data for each target gene were normalized to Actb and presented as fold change relative to 
DMSO treated sample. Error bars represent mean ± s.d. from three independent 
experiments. P values were determined by two-tailed unpaired t-test. g-h, Tumor volume 
quantification of PDXCTR-1 (g) and PDXCTR-2 (h) treated with BETi or vehicle (control). 
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Arrowhead indicates start of the treatment. P values were determined by two-tailed unpaired 
t-test. (a-c, f) or two-way ANOVA with Tukey’s post hoc test (e, g-h). Data are represented 
as mean ± s.e.m. (a-c, e, f-h).
Extended Figure 10. Model of the role for elevated NSD3 H3K36 methylation activity in LUSC 
pathogenesis.
LUSC is characterized by a number of driver mutations such as increased expression of 
PI3K and SOX2, PI3K activating mutations, deletion of PTEN and other deletions and 
alterations. One of the more common genetic alterations is amplification of the 8p11-12 
genomic region (~20% of LUSC patients). While increased expression of FGFR1 is 
postulated to be the causative mutation of the 8p11-12 amplicon, our work implicates 
amplification of the neighboring gene NSD3 as the main driving alteration. As shown, 
NSD3 amplification leads to increased NSD3 expression and hence increased synthesis of 
H3K36me2, which works in concert with other LUSC driver mutations to promote LUSC 
pathogenesis. In addition, as shown in Extended Data Fig. 2i, NSD3 overexpression is 
detected in 60% of LUSC patients, thus NSD3 is frequently highly expressed in LUSC that 
does not harbor the 8p11-12 amplifications. We also describe NSD3T1232A as a gain-of-
function (GOF) variant, that while far less common than the 8p11-12 amplicon and NSD3 
overexpression, is an alteration present in human LUSC. The NSD3T1232A variant, due to 
enhanced catalytic behavior, functionally acts like amplified or overexpressed NSD3 in 
increasing H3K36me2 synthesis and cooperating with other LUSC driver mutations to 
accelerate tumorigenesis. The increase in H3K36me2 by NSD3 overexpression or 
NSD3T1232A reprograms the chromatin landscape, blocking synthesis of H3K27me3 and 
increasing H3K36me2, which stimulates transcription of key oncogenic targets including 
genes involved in mTOR signaling and MYC-associated pathways. We speculate that 
NSD3-regulated tumors become addicted to H3K36me2-driven transcriptional activation, 
rendering these tumors particularly vulnerable to BETi as NSD3 and BRD4 interact and 
cooperate in transcription. This hypersensitivity could potentially be exploited clinically due 
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to an expanded therapeutic window for BETi and by using these drugs as targeted therapy 
for the tens of thousands of patients that are 8p11-12 positive. Not shown in the model, 
NSD3 is overexpressed in many LUSC samples without an underlying known alteration and 
we speculate that in such cases, increased NSD3 would contribute to tumorigenesis in a 
similar fashion as the scenarios described above in which NSD3 is hyperactive or 
overexpressed due to amplification.
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Figure 1. Deletion of NSD3, but not FGFR1, inhibits LUSC tumorigenesis in vivo.
a, Analysis of 8p11-12 amplified LUSC datasets from TCGA indicates increased NSD3, but 
not FGFR1, mRNA expression correlates with gene amplification (n = 85 patients). b, 
Depletion of NSD3, not FGFR1, attenuates xenograft growth of the 8p11AMP LUSC cell 
line H520. Tumor volume quantification of H520 xenografts in immunocompromised mice 
(n = 5 mice for each group). c, d, Western blots with the indicated antibodies of LUSC 
tumor lysates from PSC (control), PSCNSD3-KO (c) and PSCFGFR1-KO (d) mutant mice. Two 
independent and representative samples are shown for each genotype. Tubulin used as a 
loading control. e, Micro-computed tomography (μCT) analysis of tumor volume of the 
indicated mouse models (n = 5 mice for each group). In this and subsequent box plots, the 
line indicates the median, the box marks the 75th and 25th percentiles, and the whiskers 
minimum and maximum values. All data points are shown. P values determined by two-way 
ANOVA with Tukey’s post hoc test (b, e). f, Kaplan-Meier survival curves of PSC (n = 10, 
median survival = 200.5 days), PSCFGFR1-KO (n = 8, median survival = 202.5 days) and 
PSCNSD3-KO (n = 10, median survival = 257 days) mice, P value determined by log-rank 
test.
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Figure 2. Molecular basis of increased H3K36me2 catalysis by NSD3T1232A.
a, In vitro methylation reactions of wild-type (WT) or mutant NSD3SET using recombinant 
free histone H3 or nucleosome (rNuc) and 3H-SAM as substrates. No enzyme is a negative 
control. Top panel, autoradiography; bottom panel, Coomassie blue staining. b, Methylation 
assays on rNuc as in (a) with non-radiolabeled SAM. Westerns of reaction products shown 
with the indicated antibodies. H3 is shown as loading control. c, Methylation assays as in (b) 
with recombinant full-length wild-type or mutant NSD3. Data in a-c are representative of 
three or more biologically independent experiments with similar results. d-e, T1232A 
substitution induces widespread mobility changes on the NSD3 catalytic domain. d, Amide 
CSPs between NSD3SET-T1232A and NSD3SET is shown mapped onto the surface 
representation of the NSD3SET structure (PDB: 6CEN) with docked H3.1 residues A29 to 
R42 (stick representation). Gray: prolines and residues missing amide assignments. e, 
Changes in heteronuclear {1H}-15N nuclear Overhauser effect (NOE) values plotted on the 
structure of NSD3 as in (d) in ribbon representation. T1232 and V1243 residues are 
indicated. Uncolored residues: undetectable NOE changes.
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Figure 3. Mutant NSD3-mediated H3K36me2 synthesis promotes oncogenic programming and 
LUSC tumorigenesis.
a, Representative μCT scans at 90 and 120 days after adenoviral-Cre mediated tumor 
induction in PSC and PSCN mice. Scale bars: 10 mm. b, Quantitation of tumor volume as in 
(a) at 120 days (n = 5 mice for each group). c, Representative HE and IHC staining of lung 
tissue from PSCN and control PSC mutant mice (n = 8 mice for each group). Scale bars: 100 
μm. d, Quantification of proliferation (Ki67+-cells) as in (c). P values determined by two-
tailed unpaired t-test. (b, d). e, Kaplan-Meier survival curves of PSCN (n = 11, median 
survival = 145 days) and PSC (same data as in Fig. 1f, n = 10, median survival = 200.5 days) 
mutant mice, indicated P value determined by log-rank test. f, Western blots with the 
indicated antibodies of LUSC tumor lysates from PSCN and PSC mice. Two independent 
and representative samples are shown for each genotype. g, Western blots with the indicated 
antibodies of cell lysates from either control (sgControl) or NSD3-depleted (sgNSD3) PSCN 
cells. H3 and tubulin shown as loading controls in (f, g). h, GSEA identifies upregulation of 
hallmark gene sets: MYC targets and mTOR signaling (MSigDB: M5928, M5924) in RNA-
seq data from PSCN versus PSC tumor biopsies and PSCN cells ± sgNSD3 (n = 3 
biologically independent samples per group). Normalized enrichment scores (NES) and 
nominal P values are provided (detailed statistics description in Methods). i, CUT&RUN 
profiles of H3K36me2 (upper panel) or H3K27me3 (lower panel) over averaged gene body 
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for all genes or dDEG in PSCN cells ± sgNSD3 as indicated. j, Quantification of H3K36me2 
and H3K27me3 peak intensity change in PSCN cells ±sgNSD3 on the indicated gene sets. 
dDEG n = 234, all genes n = 16091. Two-sided t-test P value provided.
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Figure 4. NSD3 promotes human lung cell transformation and xenograft tumor growth of LUSC 
cells and PDXs and renders PDXs hyper-susceptible to BETi.
a, NSD3 depletion attenuates xenograft tumor growth of 8p11AMP and NSD3-
overexpressing LUSC cell lines. Summary of xenograft tumor growth for the indicated cell 
lines treated with sgNSD3 or shNSD3 as indicated. NSD3 levels: H, high mRNA (Z-score > 
1.0); L, low mRNA (Z-score < 1.0), scoring was consistent with relative protein levels (see 
Extended Data Figs 7a-b); xenograft tumor growth: ↓: reduced; ↔: no change (see Extended 
Data Figs. 7b-c); n.d., not determined. b, NSD3 catalytic activity required for full H520 
xenograft tumor growth. Tumor volume change of H520 xenografts reconstituted with the 
indicated V5-tagged CRISPR-resistant NSD3 derivatives in immunocompromised mice (n = 
5 mice, for each group). c, NSD3WT and NSD3TA transform SOX2-expressing AALE cells 
in vivo. Quantification of tumor size determined by bioluminescence of AALE cells grafted 
under the renal capsule and expressing the indicated plasmids plus the AkaLuc reporter (n=5 
mice for each group; see Methods). FOXE1 is a positive control, NSD3WT and NSD3TA vs. 
FOXE1 P < 0.0001. Lines denote median. d, Western blots of lysates from the indicated 
LUSC PDX samples and using the indicated antibodies. H3 and Actin are loading controls. 
e, Western blots as in (d) of lysates from PDXT1232A (left) and PDXAMP (right) ±sgNSD3 
treatment. f, g, PDX tumor volume quantification of f, PDXT1232A and g, PDXAMP 
±sgNSD3 in immunocompromised mice (n = 5 for each group). h, i, Tumor volume 
quantification of h, PDXT1232A and i, PDXAMP ±sgNSD3 and ±BETi (AZD5153 2.5mg/kg, 
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i.p.) treatments as indicated (n = 5 mice for each group). Control animals received vehicle 
(placebo) treatment. Arrowhead indicates start of the treatment. P values determined by two-
way ANOVA with Tukey’s post hoc test (b, c, h, i) or two-tailed unpaired t-test. (f, g). Data 
are represented as mean ± s.e.m. (b, f-i).
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